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CHAPTER 1
INTRODUCTION
Supercritical Fluid science and technology have given new directions in
research and applications in the last few years.Supercritical Fluid technology
is growing rapidly because of the unique physical properties of such fluids.
They can simply change from gas-like to liquid-like by adjusting the pressure
and temperature.Because of these special characteristics, supercritical fluids
are used in extractions, separations, chemical reactions, impregnation, polymer
processing, food processing, environmental remediation and pharmaceutical
production (Kiran and Brennecke, 1993).
Supercritical carbon dioxide has been chosen in the new technology
because of its several advantages: cheapness, non-toxicity and nonflammable
properties, and its availability.It is also easy to operate because of the
convenient critical temperature and pressure of carbon dioxide (I', = 31.3 °C, P,
= 72.9 atm).
One important application of SCFs is in drug formation.The Food
and Drug Administration (FDA) examines new product ingredients,
manufacturing processes, toxicological studies on animals, therapeutic claim,
and clinical trials on human beings very strictly (Ansel. Popvich and Allen, jr,
1995).The FDA has strict requirements for the use of organic solvents and
surfactants in drugs because many organic solvents and surfactants are not safe2
for humans or the environment.Organic solvents and detergents are used in
some conventional drug formulations to produce a homogeneous solution.
Therefore the FDA requires that most solvents and detergents need to be
removed from the solution before the drug can be used for human use.
Removal of such chemicals usually involves a high temperature process (spray
drying and melt pressing), which may cause drug degradation.A comparison
between conventional drug formation methods and supercritical carbon dioxide
method is shown in Table 1.1.
Itraconazole is an anti-fungal agent, which has therapeutic effects for
patients who have fungal diseases, for example, AIDS (Acquired Immune
Deficiency Syndrome) patients.It is poorly soluble in aqueous solutions and
since it is to be dissolved in gastric or intestine fluids, it is desirable to increase
its solubility in aqueous solutions.
In order to reduce drug blood level fluctuations, dosage frequency and
health care cost, controlled-release drugs have been developed rapidly.Some
drugs, such as itraconazole, need to have rapid oral absorption.Drug particles
from conventional formulation methods are larger and less porous resulting in
smaller surface area, so the drug takes longer to dissolve in the fluids of human
bodies.Sometimes the efficacy of the drug can be severely limited by its poor
aqueous solubility, and some side effects of certain drugs are due to poor
solubility.Therefore, increasing drug dissolution rate would be highly
valuable.3
Table 1.1Comparison of conventional method and supercritical carbon
dioxide method.
Conventional Method
Supercritical Carbon Dioxide
Method
Several steps, such as dissolving drug
in solvent, removal of solvent, coating
and milling or grinding.
Fewer steps.No need for solvent
removal, and drying.
Organic solvent and surfactant are
needed
SC carbon dioxide instead of
organic solvent.CO2 is safe
(nonflammable and nontoxic).
High temperature operation.
Degradation or denaturation caused by
heat or oxygen in the process.
Mild temperature condition.
High cost of solvent disposal.
Lower cost of solvent disposal (CO2
is safe).
Size reduction techniques (i.e. milling
and grinding) are needed and such
techniques usually affect the
crystallinity and chemical stability of
pharmaceuticals.
Fine particles can be produced.4
Supercritical fluid technology has the potential to solve some of the
problems associated with conventional drug formulations.The focus of this
research is forming itraconazole into a successful drug product formulation using
supercritical fluids.Itraconazole and all other ingredients are mixed with
supercritical carbon dioxide instead of an organic solvent.Higher porous
itraconazole particles can be produced in supercritical carbon dioxide.The
larger surface area of itraconazole particles should result in faster dissolution rate
of the drug in gastric fluid.Since no or little organic solvent needs to be used
in the process, the solvent-handling fee is expected to be lower.
To find the optimum treatment temperature and pressure of supercritical
carbon dioxide and the treatment time to produce itraconazole, different
experiments at different conditions were performed in this study.The
dissolution profiles of itraconazole products produced in this study were
measured for each sample in order to determine the dissolution rate of
itraconazole in gastric fluid.Dissolution studies were carried out in simulated
gastric fluids at 37.5 °C and the results compared with the commercial
itraconazole product, Sporanox, as a reference.
Chapter 2 presents an introduction toitraconazole,conventional
methods to produce the itraconazole, formulation Sporanox®, and the problems,
an introduction to supercritical fluids and a literature review of drug delivery
systems, and the controlled release of drugs.The objectives of this work are
given in Chapter 3.Chapter 4 discusses experimental materials and methods.
The results are presented in Chapter 5.Finally conclusions, and future work
are included in Chapter 6.5
CHAPTER 2
BACKGROUND AND LITERATURE REVIEW
Itraconazole formulation development includes several steps: solubility
study in SC CO2, formulation study, drug formation methods, drug delivery
system and dissolution study.Then there will be some clinical investigations
and drug regulatory evaluation before going to market.Those steps are shown
in the flow chart (Fig 2.1).Formulation study has been done in the Pharmacy
Department.This study focused on supercritical fluids technology and
dissolution study.Drug delivery systems development will be studied in the
future.SCF technology is introduced in Chapter 2.1.Chapter 2.2 discusses
drug delivery systems.Chapter 2.3 is the introduction of itraconazole.
Chapter 2.4 includes conventional methods to produce itraconazole and its
problems.Solubility Study
in SC CO2
Drug Formation
Using SC CO2
Drug Delivery Systems
Study
Formulation Study
(Pharmacy)
Dissolution Test
Measurement
\......
6
Figure 2.1 Flow chart of itraconazole development.7
2.1 Supercritical Fluids
A pure supercritical fluid is a substance, which is heated and
compressed above its critical point (including its critical temperature Tc and
critical pressure Pr).Above its critical point, it is neither a liquid nor a gas, but
a fluid changing continuously from liquid-like to gas-like as its pressure
decreases.The phase diagram of a single substance is shown in Figure 2.2.In
the diagram, C represents the critical point, and T represents the triple point.
Curve TC means the gas-liquid coexistence curve when liquid and gas are in
equilibrium.As both the temperature and pressure are increased, curve TC
tends towards C.The liquid becomes less dense because of the effect of
thermal expansion and the gas becomes denser due to the increasing pressure.
SCFs can have better mass transfer through a porous matrix due to the higher
diffusivities than normal liquids (Saad and Gulari, 1984).Because the densities
of SCFs are higher than normal gases, SCFs can facilitate higher solubility than
gases.The densities of liquid and gas phases become equal (called critical
density, p c) at the critical point and the substance becomes a supercritical fluid.
The values of densities, solubility and other physical properties in the
supercritical region are between those of typical liquids and gases.A
comparison of SCF and typical gas and liquid is presented in Table 2.1.
Supercritical Fluids Technology offers a convenient way to change
solvating properties from gas-like to liquid-like without changing chemical
structure (McNally and Bright, 1992).Therefore, Supercritical Fluids
Technology has grown rapidly.8
Table 2.2 presents the critical parameters (critical temperatures, critical-
pressure and critical densities) of some compounds as supercritical fluids.The
most popular compound today is carbon dioxide because of its low critical
temperature, non-toxicity, non-flammable property and cheapness.The carbon
dioxide molecule is non-polar so it is a non-polar solvent.However, it has
some affinity with polar solutes due to its large molecular quadrupole
(Westwood, 1993).Therefore, pure carbon dioxide can be used to dissolve
many large organic solutes.The most popular application currently is the
extraction and recovery of polar organic compounds from aqueous media.In
industries, supercritical carbon dioxide technology is used for separation of
natural components, such as caffeine from coffee beans and rose oil from roses.
Table 2.3 shows some applications.Drug product formulation has caught much
attention in application of SCFs Technologies in past years.9
Solid
Pc
Liquid
C
TC Gas
SCF
Critical Point
Tc
Temperature (°C)
Figure 2.2Phase diagram of a single substance.
Table 2.1A comparison of physical properties of SCFs, a typical gas and
liquid (Westwood, 1993).
Phase Gas SCF Liquid
Diffusion Coefficient (cm2/s) 10-1 10-3 10-5
Density (g/cm3) 10-3 0.2-0.9 1.0
Viscosity (mPa s) 10-2 10-2-10-1 1.010
Table 2.2Critical parameters of some useful compounds as SCFs
(Anderson, 1993).
Substance Te (°C) Pc (MPa) p c (10 Kg/m)
CO2 31.30 7.39 0.47
N20 36.50 7.35 0.45
SF6 45.50 3.76 0.74
NH3 132.50 11.40 0.24
H2O 374.00 23.00 0.34
n-C4Hio 152.00 3.80 0.23
n-051112 197.00 3.78 0.23
Xe 16.60 5.92 1.10
CC12F2 112.00 4.13 0.56
CHF3 25.90 4.75 0.5211
Table 2.3Commercial-scale supercritical CO2 extraction processes
(Anonymous, 1995).
Process I Plant Location
Coffee Decaffeination
Bremen, Germany (two plants),
Italy, Poszzillo, Houston and Texas
Tea Decaffeination Germany and Munchmuenster
Fatty Acids from Spent Barley Dusseldorf and Germany
Nicotine Extraction Hopewell and Virginia
Rose-Residual Oil SCE Oklahoma City
CO2 Refining of Extracted
Pyrethrum
United Kingdom
Hops Extraction and Spices
Australia, Germany (two plants),
Melbourne, Munchmuenster,
Reigat, United Kingtom, Wolnzach,
Nebraska, Washington (two plants)
and Yakima
Flavors Extraction France and Grasse
Flavors/Aromas Germany and Rehlingen
Corn Oil Japan
Color Extraction-Red Pepper Japan (six plants)12
2.2 Drug Delivery Systems
After producing effective drugs, the next step will be to develop the best
drug delivery system for the specific drug and control drug release at the desired
rate, which can enhance the efficacy of therapeutic agents through controlled
release.Drug delivery systems refer to the technology utilized to deliver drugs
to the desired site inside the body for drug release and absorption.The
difference between the approach of the classical or traditional drug discovery
process and new ones is that screening systems now are much more selective,
involving the use of in vitro receptor binding techniques and enzyme inhibition
assays.In order to develop the successful dosage forms, it is convenient to use
delivery route as a meaning of classifying drug delivery issues.There are site-
specific, implantable, ocular, transdermal, intranasal, sublingual, buccal,
intravenous, intramuscular, subcutaneous, inhalation, and oral delivery systems,
etc.The site-specific delivery systems deliver drugs directly to affected tissues.
Implantable drug delivery systems are placed completely under the skin-usually
in a convenient but inconspicuous location.They are small solid dosage forms
containing concentrated drug and they continuously release their medication
over prolonged periods without repeated insertion of needles.Ocular drug
delivery includes drug-impregnated membranes.Transdermal supports the
passage of drug substances from the surface of the skin through its various layers
and into the systemic circulation.Drug materials applied topically to the nasal
conjunctiva will enter the nose through the nasolacrimal duct just beneath the
anterior end of the inferior turbinate.Sublingual drug delivery systems are to
put drugs under tongue.Buccal drug delivery is to place drug tablets at the13
sides inside mouth.Intravenous drug delivery is to inject drugs directly into
blood.Intramascular delivery systems are to inject drugs directly into muscles.
Subcutaneous drug delivery systems deliver drug into skin by injection.
Inhalation drug delivery is to spray drugs through mouth.Oral is, and will be
the most convenient and commonly employed route of drug delivery systems.
There are many technologies available for oral drug delivery systems from
liquids, capsules and tablets through various sustained-release systems to highly
sophisticated osmotic devices (Gardner, Sharp, Laboratories and Point, 1987).
The oral drug delivery system is also the system chosen in this study.
2.3 Itraconazole
Itraconazole (C35H38C17N504, molecular weight = 705.64) is a synthetic
triazole anti-fungal drug (Figure 2.3).Itraconazole is a white to slightly
yellowish powder.It consists of a 1:1:1:1 racemic mixture of four
diastereomers, each of which has three chiral centers.Itraconazole is highly
lipophilic so it is barely soluble in aqueous solutions (less than 100 mcg /100 mg
in aqueous media within PH = 1-12.7).It is most soluble in dichloromethane
(25 mg /100 mg).The solubility of itraconazole in various solvents and in
aqueous media is shown in Table 2.4.Itraconazole is a weak base (pKa = 3.7)
and has a log C (n-octanol/water) partition coefficient of 5.66 when PH = 8.11
(Kapsi. 1998).It can distribute extensively in tissues and especially is found in
higher-level tissues, such as in brain.The half-life of itraconazole, the time
required for the drug's blood or plasma concentration to decrease by one half is
very long (about 20 hours).Itraconazole can inhibit cytochrome14
P-450-dependent metabolism of ergosterol, which is a vital component of fungal
cell membranes, and then interfere in sterol biosynthesis causing the death of
cells inside the membranes of cells (Kapsi, 1998).Clinical use of itraconazole
is treatment of fungal infections in immunocompromised and
non-immunocompromised patients.Patients who have blastomycosis,
pulmonary, extrapulmonary, histoplasmosis and aspergillosis diseases can take
itraconazole.Itraconazole is also used for patients with onychomycosis of the
toenail with or without fingernail involvement due to dermatophytes (marketed
itraconazole, Sporanox).
Figure 2.3Chemical structure of itraconazole.15
Table 2.4Itraconazole solubility in different solvents and aqueous media
(Kapsi, 1998).
Solvent Solubility in g/100m1 Solution
Water (PH = 7.0) <0.0001
Hexane <0.001
Diethyl ether 0.002
2-propanol 0.008
Polyethylene glycol 400 0.013
Tetrachloroethane 0.013
Ethanol 0.026
4-methyl 2-pentanone 0.058
Methanol 0.061
Acetonitri le 0.11
Toluene 0.12
Ethyl acetate 0.16
Polyethylene glycol 400 0.19
2-propanone 0.20
2-butanone 0.23
Dimethyl sulfoxide 1.1
Tetrahydrofuran 2.2
N,N-dimethyl formamide 3.5
Dichloromethane 2516
2.4 Conventional Method and Problems of Producing Itraconazole and
Formulations
From Table 2.4, it is seen that itraconazole is most soluble in
dichloromethane (methylene chloride); however, it is poorly soluble in water,
and other aqueous or organic solvents.In today's pharmaceutical industry, the
existing formulation of itraconazole is Sporanox produced by Janssen
Pharmaceutica.A solution was prepared by adding itraconazole powder and
hydroxypropyl methylcellulose (1:1.5) into dichloromethane and denatured
ethanol (60:40) while stirring.Another seal-coating spraying solution with
dichloromethane and polyethylene glycol 20000 (5.4:1) were prepared while
stirring, denatured ethanol was added, and the solution was stirred until
homogeneous.The itraconazole solution was sprayed to the spheres of sugar
beads and then those sugar beads were dried to remove dichloromethane at a
temperature of about 80 °C and at a pressure of about 200-300 mbar (20-30 kPa).
The prepared seal-coating solution was then sprayed to the itraconazole
containing beads from the former step, and dried again at 50-55°C.Because
itraconazole has very low solubility in other aqueous or organic solvents, sticks
together easily after the process, and precipitates in gastric fluids, HPMC was
added as a hydrophilic agent as well as to avoid precipitating, and polyethylene
glycol 20000 (PEG) was added to prevent the drug loaded beads from sticking
together.The biggest problem here is the use of dichloromethane because the
FDA has very strict requirements for minimum presence of dichloromethane
(less than 0.005 %).Therefore a drug delivery system without the use of highly
regulated organic solvents needs to be developed.Another problem is too
many steps in this process.In addition, it is known that itraconazole needs a17
faster release in gastric fluids because it is only 56 % bioavailiable.Using SCF
technology has solved those problems.18
CHAPTER 3
OBJECTIVES OF THIS RESEARCH
The goal of this study is to develop an immediate release delivery
system for itraconazole.There are three main objectives summarized below:
Objective 1
Avoid the use of organic solvents to develop a product of the
water-insoluble anti-fungal agent, itraconazole while is bioequivalent to
Sporanox.Carbon dioxide will be used instead of methylene chloride.
Objective 2
Find the optimum operating conditions in this itraconazole formulation
production process, including temperature, pressure, treatment time, mixing and
flow.
Objective 3
Meet the itraconazole dissolution requirement: higher than 80 % drug
dissolution at 45 minutes in simulated gastric fluid at 37.5 °C, 100 rpm.19
CHAPTER 4
EXPERIMENTAL MATERIALS AND METHODS
4.1 Introduction
This research was designed to produce on itraconazole formulation,
which has high dissolution in simulated gastric fluid (higher than 85 % at 45
minutes).The optimum extraction pressure and temperature were found during
SCF extraction of itraconazole.In this chapter, the experimental apparatus,
methods and materials used in this study to form what itraconazole are discussed.
Section 4.2 discusses the itraconazole formulation used in this study.Section
4.3 describes the equipment used for the treatment of itraconazole formulation
with SC CO,.Experimental method is discussed in section 4.4 and the last
section of this chapter explains the chemicals used in this study.
4.2 Formulation of Itraconazole Formation
Ingredients used in the itraconazole formulation have been studied by
Shivakumar Kapsi in1998 inthe college of Pharmacy at Oregon State
University. Theformulationincludesfiveingredients:itraconazole,
polyethylene glycol 20000 (PEG), a hydrophilic polymer, a super disintegrated
sodium starch, and a wetting agent.PEG 20000 was selected between PEG
3350, 8000 and 20000 because itraconazole dissolution in gastric fluid improved
considerably(10 %) asthe molecular weight of PEG increased.The
hydrophilic polymer was found to prevent precipitation of the drug during
dissolution.The sodium starch was added to speed up drug release in gastric20
fluid.A wetting agent has been chosen to enhance the solubility of the drug
(Kapsi. 1998).The problem of this method was the difficulty of controlling
treatment temperature and high temperature may cause degradation of drug.In
this study. treatment temperature was well controlled by the SCF Extraction
system.SC CO, is added to the above formulation in order to increase drug
dissolution and enhance drug release in gastric fluid.
4.3 Supercritical Fluid Extraction System
The schematic diagram of experimental apparatus is shown in Figure
4.1.This equipment consists of a SCF Extractor (SFXTM 2-10) and a syringe
pump and controller system (ISCO 2601)).Supercritical Fluid Extractor is
made for high-temperature and high-pressure usage.It consists of an oven for
heating. a temperature controller and two 10-m1 stainless steel cells.The
syringe pump from ISCO was used to feed carbon dioxide to the extractor.The
pump system consisted of a control panel to set the pressure or flowrate.The
pressure range was 10 to 7,500 psi and the pressure accuracy was ±2 % of full
scale (ISCO manual).A vial was connected to the extractor to collect samples.Syringe Pump
CO, Supply
Treatment system
Figure 4.1 Schematic diagram of experimental equipment.
Vent
Vial
214.4 Experimental Method
A simple one-step extraction method was used in this study.There
was no secondary solvent removal step required using this method.Therefore,
all waste disposal fees were eliminated.First a desired amount of sample
including all ingredients (itraconazole, PEG 20000, the hydrophilic polymer, the
sodium starch and glycerol) was loaded into thecell and mixed before
introducing the treatment system.The syringe pump was then filled with
carbon dioxide from a supply cylinder.Parameters, such as cell temperature
and pump pressure. were settothe desired values.Carbon dioxideat
supercritical conditions was added to the cell.After treatment equilibrium was
reached (about 15 minutes). supercritical solution was allowed to flow into the
vial.To generate mixing in the cell. flow rates of 0.5 to 2.0 ml/min were used
in all experiments.After a desired period of time, the pressure in the cell was
suddenly dropped to atmospheric pressure.
The solution in the cell was cooled by a cooling system Dionex SFE
703 or in dry ice.The product was ground in a blender (Waring commercial
laboratory blender) and particle ranging in size between 0.2-1 mm were sieved
through two different meshes.Dissolution profiles of itraconazole release were
obtained using the United States Pharmacopoeia (USP) XXII apparatus II (VK
7000®, Vankel Industries, Inc., Edison, NJ).The dissolution measurement was
a paddle stirring method as shown in Figure 4.The equipment of VK 7000 is
shown in Figure 4.2.Dissolution media consisted of 900 ml of enzyme-free
simulated gastric fluid (PH = 1.4 ± 0.1) maintained at 37 °C.The solution was
mixed at 100 rpm for 60 minutes.3 ml dissolution samples were collected at 5.23
diluted to 10m1 with simulated gastric fluid.Finally, thel0 ml diluted solution
was taken for UV analysis at a fixed wavelength of 226 nm using a Beckman
DU-600 spectrometer.24
Control panel
ltraconazole product filled in a capsule
Gastric Fluid
Temperature = 37.5 °C
Agitating Speed = 100 rpm
\_./.Circulating Water
Figure 4.2 Schematic diagram of dissolution apparatus.4.5 Source of Materials
Grade 2.8-carbon dioxide was purchased from Industrial Welding
Supply (Albany. Oregon).Itraconazole powder was provided by College of
Pharmacy, Oregon State University.Polyethylene glycol 20000 was purchased
from Sigma Chemical Co, St. Louis.Sodium starch was purchased from
Edward Mendell Co.The hydrophilic polymer was from Dow Chemical Co,
Midland. and the wetting agent was provided by Sigma Chemical Co, St. Louis.26
CHAPTER 5
RESULTS AND DISCUSSION
Thedissolutionprofileofinnovatoritraconazoleformulation
(Sporanox ®) is shown in Figure 5.1.90 % itraconazole was dissolved in gastric
fluid after 60 minutes.Better products, which have higher dissolution and
faster drug release than Sporanox® were produced.This chapter presents in
this study important results obtained from scanning electron microscopic
pictures and dissolution measurements is divided into five sections.The first
section presents two different ways to show the effect of carbon dioxide on the
product formed and its dissolution profiles; the particle morphology and solvent
power.The second section shows the effect of treatment temperature.The
effect of treatment time is explained in the third section.The next section
discusses how mixing during the treatment process affects the dissolution
profiles of itraconazole.The last section shows the effect of two cooling
methods on the dissolution results after the drug was formed.The solubility of
itraconazole in SC CO2 is low because no drug was found in the collecting vial.
However, SC CO2 is soluble in drug solution because it was visually seen CO2
coming out of the drug solution when dropping the pressure after treatment.
The solubility of SC CO2 in drug solutionisa function of treatment
temperatures, treatment pressures, treatment time and mixing.The products
from SC CO2 method are white and porous solid.96 % of the chemicals were
recovered. Yellowish solid would be formed due to high treatment temperature
(>140 °C) or long treatment time (> 30 minutes).27
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Figure 5.1 Dissolution profile of itraconazole from innovator product,
Sporanox.28
5.1 Effect of Carbon Dioxide
Supercritical carbon dioxide has significant effect on the itraconazole
and its dissolution profile. This fact can be proved from two ways: the particle
morphology, and solvent power.
5.1.1 Particle Morphology of Itraconazole Products
Scanning electronmicroscopic (SEM) photomicrographs of two
different samples are shown in Figures 5.2 and 5.3.The sample in Fig. 5.2 was
without supercritical carbon dioxide and that in Fig. 5.3 was treated with carbon
dioxide at 300 atm.The one without SC CO2results in a solid network
consisting of intertwining aggregated cubes.The morphology in Fig. 5.3
consists of many thin layers with small pores inside.The different morphology
inFig.5.3 was duetotheeffectof CO2 during thetreatment and
depressurization.The expansion of the drug solution by depressurizing SC
CO', produced more porous products.BET surface area measurement is needed
to quantify the actual surface area of these samples.29
Figure 5.2 SEM photomicrograph of itraconazole formed at the treatment
condition: without SC CO2, T = 135 °C and t =10 minutes.30
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Figure 5.3SEM photomicrograph of itraconazole formed at the treatment
condition : with SC CO2 (P = 300 atm), T = 135 °C and t = 10
minutes.
To see the effect of CO2 on dissolution profile, experiments were
performed with and without CO2 at different conditions and the results are
presented in Figures 5.4, 5.5 and 5.6.These figures show that the amount of
dissolved drug in gastric fluid increases significantly (23-40 %) in one-hour
dissolution experiment with CO2 at 300 atm compared to runs without CO2.
Results from dissolution measurement and SEM photomicrographs of the
product prove that CO2 has significant effects on the morphology of the drug and
its dissolution profile.Figures 5.4, 5.5 and 5.6 are all the same P, T, treatment31
time but they differ in whether explotab was added at the end (Fig. 5.4) and if
there was mixing during heating process (Fig. 5.6).Figure 5.6 is without
mixing during heating process and explotab was added at the beginning with
other ingredients.Fig. 5.4 shows that the drug precipitated after 20 minutes.
Product, that precipitate in gastric fluid are not desirable and thus explotab was
added to the ingredients at the beginning of the process in all other experiments.
From Figures 5.5 and 5.6, it can be concluded that mixing during heating process
did not have significant effect on the products, and thus the other experiments
are wither with mixing or without mixing during the heating process.
In Figures 5.4, 5.5 and 5.6, the itraconazole dissolution in gastric fluid
were much higher when CO, was used during the treatment conditions compared
to runs without CO2.This shows that the use of CO2 enhances the dissolution
rate of the product in gastric fluid.Another way of showing the importance of
CO2 is to look at the temperature needed to obtain the same dissolution rates
with and without CO2 (Fig. 5.7).As shown in the figure, almost the same
dissolution profiles are obtained for drugs produced with and without CO2.
However, the drug produced with CO2 requires 15 °C lower temperature than
that produced without CO,.As higher temperatures (> 140 °C) may result in
drug decomposition, the product produced with CO2 is more favorable.The
time delay in Fig. 5.7 is due to the fact that the capsule dissolved about 1-4
minutes slower than the other samples after it was placed in gastric fluid.32
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Figure 5.4 Dissolved amount of itraconazole as a function of time.
Treatment conditions: with CO2 (P = 300 atm) or without
CO2, T = 130 °C, t = 10 minutes and add explotab at the
end.33
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Figure 5.5 Dissolved amount of itraconazole as a function of time.
Treatment conditions: with CO2 (P = 300 atm) or without
CO2, T = 130 °C and t = 10 minutes and without mixing
during heating process.34
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Figure 5.6 Dissolved amount of itraconazole as a function of time.
Treatment conditions: with CO2 (P = 300 atm) or without
CO2, T = 130 °C, t = 10 minutes and with mixing during
heating process.120
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Dissolved amount of itraconazole as a function of time.
Treatment conditions: with CO2 (P = 300 atm, T = 135 °C)
or without CO2 (T = 150 °C), t =10 minutes and with
mixing during heating process.
5.1.2 Solvent Power
Solvent power is the strength of solvent for dissolving solutes.A SEM
photomicrograph of the product formed at a subcritical pressure (P = 30 atm) is
presented in Figure 5.8.The picture shows two kinds of morphologies.On
the right side is a network of aggregated cubes similar to Figure 5.2.The left
side consists of some large pieces with a few pores inside.Fig. 5.8 seems to be
a combination of Fig. 5.2 and Fig. 5.3.The significantly different
morphologies observed in Figures 5.8 and 5.3 may due to the different solvent
powers at the to pressures.36
Figures 5.9, 5.10 and 5.11 present the dissolved drug as a function of
time at different treatment pressures.Higher operating pressures give higher
dissolution rates because the solvent strength increases and more SC CO? gets
into the drug solution as pressure increases.Results from these figures show
that CO2 and its solvent power are important in producing a product with a high
dissolution rate in gastric fluid.From Figures 5.9 and 5.10, the drugs that were
conditioned to a pressure of 400 atm precipitated in gastric fluid.Therefore,
pressures above 300 atm were not used in proceedingexperiments.
Fig. 5.9 shows a much lower (about 30-60 %) dissolution than Figures
5.10 and 5.11 due to the lower temperature used in Figure 5.8 (120 °C compared
to 130 and 135 °C).Temperature was an important parameter on dissolution of
the product in gastric fluid because solubility of itraconazole in the solution is a
strong function of temperature.Effect of temperature on dissolution profile is
discussed in section 5.2.D:4,200x
P:1,500x
C"
9 MAR 100
*0006
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Figure 5.8SEM photomicrograph of itraconazole formed at the treatment
condition: with CO2 (P = 30 atm), T = 135 °C, t = 30 minutes.38
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Figure 5.9 Dissolved amount of itraconazole as a function of time.
Treatment conditions: P = 200, 300 and 400 atm, T = 120
°C, t = 10 minutes, without mixing during heating process
and with flow.39
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Figure 5.10 Dissolved amount of itraconazole as a function of time.
Treatment conditions: P = 200, 300 and 400 atm, T = 130
°C, t = 10 minutes, without mixing during heating process
and with flow.40
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Figure 5.11 Dissolved amount of itraconazole as a function of time.
Treatment conditions: P = 30, 200 and 300 atm, T = 135
°C, t = 30 minutes, with mixing during heating process
and with flow.41
5.2 Effect of Temperature
Two SEM photomicrographs of samples formed at two different
treatment temperatures are shown in Figure 5.12 and 5.3.The product formed
at the lower temperature (120 °C) (Figure 5.12) consists of intertwining solid
pieces, which may have lower porosity and surface area.Dissolved
itraconazole as a function of time at various treatment temperatures are shown in
Figures 5.14, 5.15 and 5.16.From Figure 5.14, the dissolution profile of the
product at 140 °C resulted in precipitation of itraconazole in gastric fluid;
therefore, this temperature has been eliminated in later experiments.Higher
treatment temperatures showed higher dissolution of drug in gastric fluid due to
the fact that more itraconazole would dissolve in PEG solution at high
temperatures. Of course temperatures of 140 °C and higher may result in
decomposition or degradation of drug.The optimum temperature was found to
be 135 °C.42
Figure 5.12 SEM photomicrograph of itraconazole formed at treatment
condition: P = 300 atm, T = 120 °C and t = 10 minutes.43
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Figure 5.13 SEM photomicrograph of itraconazole formed at treatment
condition: P = 300 atm, T = 135 °C and t = 30 minutes.100
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Figure 5.14Dissolved amount of itraconazole as a function of time.
Treatment conditions: T = 110, 120, 130 and 140 °C, P =
200 atm, t = 10 minutes, without mixing during heating
heating process and with flow.45
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Figure 5.15 Dissolved amount of itraconazole as a function of time.
Treatment conditions: T = 110, 120 and 130 °C, P = 300
atm, t = 10 minutes, without mixing during heating
process and with flow.46
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Figure 5.16 Dissolved amount of itraconazole as a function of time.
Treatment conditions: T = 120, 130 and 135 °C, P = 300
atm, t = 10 minutes, with mixing during heating process
and with flow.
5.3 Effect of Treatment Time
Figures 5.3 and 5.13 present the different morphology of the products
produced at different treatment times. No notified difference in morphologies
was observed. Effect of treatment time on dissolution profile of itraconazole in47
gastric fluid is shown in Figures 5.17 and 5.18. The amount of dissolved
itraconazole in gastric fluid increased with the increase of treatment time, except
for one-hour treatment time. One-hour treatment time may cause decomposition
of drug due to a long exposure of drug to a high temperature and formed
yellowish product. Therefore, the optimum treatment time was found to be 30
minutes.
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Figure 5.17 Dissolved amount of itraconazole as a function of time.
Treatment conditions: t = 10 or 30 minutes, T = 130 °C,
P = 300 atm, without mixing during heating process and
with flow.48
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Figure 5.18 Dissolved amount of itraconazole as a function of time.
Treatment conditions: t = 10, 20, 30 and 60 minutes, T =
135 °C, P = 300 atm, with mixing during heating process
and with flow.49
5.4 Effect of Mixing during Treatment
Dissolution profile of itraconazole formed with CO2 flow (0.5-2 ml/min) or
without CO2 flow during the treatment process is shown in Figure 5.19. Having
a small CO2 flow rate2 ml/min) resulted in higher dissolution rates. Flow of
SC CO2 through the treatment cell may generate a better mixing of the
ingredients leading to a product, which contains more itraconazole and has a
higher dissolution rate in gastric fluid.
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Figure 5.19 Dissolved amount of itraconazole as a function of time.
Treatment conditions: with flow (0.5-2 ml/min) or without
flow, T = 135 °C, P = 300 atm, t = 30 minutes and with
mixing during heating process.50
5.5 Effect of Cooling
When the treatment process is completed, the solution must be rapidly
cooled to entrap the drug in solution in the interstitial spaces of PEG 20000. To
see the effect of cooling rate on dissolution profile of itraconazole in gastric
fluid, two different cooling methods were used. Cooling in Dionex (-6 °C) or
dry ice (-57 °C) did not have a considerable effect (about 3 %) on the dissolution
of drug in gastric fluid (Fig. 5.20). Cooling in Dionex system was selected for
all other experiments.
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Figure 5.20 Dissolved amount of itraconazole as a function of time.
Treatment conditions: cooled in dry ice or Dionex, T =
130 °C, P = 300 atm, t = 10 minutes, without mixing
during heating process and with flow.51
CHAPTER 6
MODEL DEVELOPMENT FOR ITRACONAZOLE RELEASE
6.1 Introduction
It is well known that drug availability in the market is usually
determined by the dissolution rate of the drug from the dosage form.The
release of drug from a drug product may be influenced by the physical and
chemical properties of the drug dosage form.Also, the release of a drug from
its physical structure is determined by the rate at which it dissolves in the
surrounding medium (Banakar, 1992).The rate of dissolution of a drug is
defined as the amount of the drug substance going into the solution from a solid
state per unit time in standard conditions.In this study, a simple but clear
intrinsic dissolution model was developed to define itraconazole dissolution in
the gastric fluids.
6.2 Mathematical Model Used for Dissolution Profile
The intrinsic dissolution model was chosen in this study.Dissolution
rate involves some physical parameters, such as interfacial area, shape and the
substance and the solubility of the substance in the solution.Dissolution can be
described as a heterogeneous system resulting in a net effect of mass transfer
from the escape from the surface of small drug particles to solution.It can be
expressed mathematically as
dM
= kA(C,C)
di
(6.1)or
dC
V = kA(C,C)
dt
52
(6.2)
where V is the volume of the solution; M is the mass of drug substance in the
solution; A is the interfacial surface area of drug; C, is the saturation
concentration usually referred to as solubility in the medium; C is the
concentration dissolved into the solution at any time t; and k is the
convective-mass transfer coefficient.
In this model, the capacity coefficient, kA was assumed to be constant
during the dissolution process because the solution was a very dilute system as
the amount of dissolved drug into the solution medium was small compared to
the 900-m1 gastric fluid.Therefore. the volume of the solution was also
assumed to be constant.
The initial and final conditions in this study were C = 0 at t = 0 and C =
Csat t= co.
Rearranging equation (6.2) gives
Give
dC= a(C,C)
dt
where a = k(A/V)
(6.3)
Integrating equation (6.3) and applying the initial and final conditions
C = Cs(I ) (6.4)53
C, was experimentally determined by keeping the itraconazole formulation for
about two days in gastric fluid.Two products were used to determine C,.One
product was obtained at the best treatment condition (T = 130 °C. P = 300 atm, t
= 30 minutes, with mixing during heating process and with flow during
treatment), and the other product was obtained without CO, (T = 150 °C) to
obtain the same dissolution profile.The average of C of two products was
140.3744 mg/L.
The R-square fitting method was used to find the parameters, a.The
equation is expressed mathematically as
R' =I
SSE
SST
(6.5)
where SSE is the sum of the squares of the errors. and SST is the sum of the
squares of deviations.
The mathematical definition for SSE and SST are as follows
SSE =(Ci
Ergor,/ )2 (6.6)
SST = I(CiExPCE'P ) 2 (6.7)
where CiE' is the experimental concentration at time t and Cicai is the calculated
concentrationatthesametime. CE(Pistheaverageexperimental
concentration.54
6.3 Results and Discussion
The time delay happened sometimes in dissolution test due to the fact
that capsules dissolved in gastric fluid slower (1-4 minutes).Those dissolution
profiles have been shifted to correct the time delay before model fitting.
Parameters a and R2 for different treatment conditions are tabulated in
Table 6.1.Experimental and predicted values of dissolved itraconazole in
gastric fluid for different treatment times are shown in Figure 6.1.The model
for 30-minute treatment condition fitted the data very well (the R-square =
0.9597).The model can fit better for longer treatment time.Experimental
and calculated dissolution profile for different treatment temperatures are shown
in Figure 6.2.The model for the highest treatment temperature (T = 135 °C)
fitted the model best (R-square = 0.9458).The model can predict better fit for
higher treatment temperature condition.A similar comparison plot was
generated for the treatment pressures (Fig. 6.3).The model for the highest
treatment pressure fitted the model very well (R-square = 0.9597).55
Table 6.1Calculated parameters of the intrinsic model
Conditions during the treatment Parameters of the model
P (atm)
T
(°C)
Treatment
Time (min)
MixingFlow a R2
300 135 30 Yes Yes 0.046115 0.9597
300 135 20 Yes Yes0.041999 0.9378
300 135 10 yes Yes0.022093 0.9458
300 130 10 Yes Yes0.023569 0.8409
300 120 10 Yes Yes0.008953 0.2697
200 135 30 Yes Yes 0.013422 0.5045
30 135 30 Yes Yes 0.008908 0.194556
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Figure 6.1 Experimental and calculated dissolved amount of itraconazole
as a function of time. Treatment conditions: t = 30, 20 and
10 minutes, T = 135 °C, P = 300 atm, with mixing during
heating process and with flow.57
100
90
80
70
60
50
40
30
20
10
Figure 6.2 Experimental and calculated dissolved amount of itraconazole
as a function of time. Treatment conditions: T = 135, 130
and 120 °C, P = 300 atm, t = 10 minutes, with mixing during
heating process and with flow.58
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Figure 6.3 Experimental and calculated dissolved amount of itraconazole
as a function of time. Treatment conditions: P = 300, 200
and 30 atm, T = 135 °C, t = 10 minutes, with mixing during
heating process and with flow.59
CHAPTER 7
CONCLUSIONS AND RECOMMENDATIONS
7.1 Conclusions
A new method was developed to form a soluble anti-fungal agent,
itraconazole, using pure supercritical carbon dioxide, instead of highly regulated
organic solvents.This method was easy to operate because the treatment
temperature and pressure were well controlled by ISCO SI-L Extractor system.
All the samples were formed using the same formulation in this study,
but the amounts of itrconazole dissolved in the drug solution at different
treatment conditions were different and this explains why some products have
lower dissolution rate than the others.
100 % itraconazole dissolution in one-hour was achieved at the
treatment condition: T= 135 °C, P = 300 atm, t = 30 minutes, with mixing during
heating process, with flow and cooling in Dionex system.SC CO, treatment
improved dissolution of itraconazole in gastric fluid by 23-40 %.This increase
in dissolution rate was due to the solvent power of CO, and possibly the higher
porosity of the products.Higher pressure gives higher solvent power, but
treatment pressures in excess of 300 atm caused precipitation of drug in gastric
fluid.In order to get the same dissolution, the product without SC CO2
treatment had to be produced under higher treatment temperature (15 °C higher).
Treatment temperature also has a significant effect on dissolution results.
Temperatures higher than 140 °C may degrade the drug or cause precipitation in
gastric fluid.Low temperatures (<120 °C) resulted in low dissolution rates of60
itraconazole in gastric fluid.Therefore. the optimum treatment temperature
was found to be 135 °C.Treatment time when used with a high temperature
was proved to be an important factor on dissolution results.The product at 135
°C treated for 30 minutes obtained 25 % higher dissolution than one, which was
treated for 10 minutes.Mixing during the treatment was also found to be an
important effect to improve the dissolution.Due to the equipment limitations,
mixing was generated by flow rate of the SC solution.The dissolution
increased 20-25 % when mixing was generated.Rapid cooling can trap
itraconazole in the solution in the interstitial spaces of PEG 20000.However.
the dissolution was not significantly affected by the cooling rate.
An intrinsic dissolution model was developed with different parameters
(a) at higher treatment temperature, pressure and longer treatment time and was
tested to be able to predict the dissolution profiles of itraconazole in gastric fluid.
The R-square values ranged from 0.1945 to 0.9597.
7.2 Recommendations
BET surface area measurements would be useful in correlating
products' surface area to dissolution profile.61
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APPENDICESAppendix A: Standard Curve of Itraconazole
Preparation
65
20 mg raw itraconazole dissolved in 200 ml acetonitrile completely gave
100 % dissolution for 100 mg itraconazole in 1 L simulated gastric fluid.The
solution was diluted in to 10, 20, 40, 60, and 80 %.Those solutions were tested
for UV absorbance at fixed wavelength, 226 nm, using a Beckman DU-600
spectrophotometer.
Standard Curve Data
Standard Concentration
(1m1 drug /IL gastric fluid)
Absl Abs2Absorbance
at 226nm.
Estimated
Value
% Theory
10 0.042450.044240.043359.9433399.43333
20 0.089310.089980.0896520.23222101.16111
40 0.182510.181950.1822340.80667102.01667
60 0.265610.266240.2659359.4055699.00926
80 0.365690.362550.3641281.22667101.53333
100 0.451390.450880.45114100.56333100.56333
Average100.61951
Standard
Deviation
1.19025
%C.V. 1.18293Standard Curve of Itraconazole
0.5
0.4
0.3
0.7
0.1
0
0
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Appendix B: Calculation for Dissolved Percent of Itraconazole in
Gastric Fluid
Those dissolution experiments of 100 mg itraconazole were carried out
in 900 ml gastric fluid so the standard data were converted into the same ratio.
The absorbance correction of 100 % dissolution is below:
The 100 % standard absorbance in 900 ml gastric fluid = 0.45114 (the
absorbance for 20 mg itraconazole in 200 ml acetonitrile) x 1000 ml/ 900 ml =
0.5012667
Those absorbance data were converted into percent of 100 mg
itraconazole dissolved in gastric fluid by following formula:
Percent = (absorbance at any time / 0.5012667) x 100%68
Appendix C: Data of Dissolution Study
Formulation: Itraconazole + PEG 20000 branched chain + Glycerol +
HPMC (K I5M) + Explotab
Device: ISCO cell69
Conditions during the Treatment Dissolution Study Data
P (atm)T ("C)
Treatment
Time
(min)
MixingHowCooling
...1 Ti me E.-
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
30 135 30 Yes Yes ,2 Dionex-Beginning
50.0790.07515.7215.06
100.1520.13830.3427.48
200.1640.16232.6232.38
300.1710.17434.1334.73
450.1720.18134.2336.18
600.1740.18234.7536.33
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Ti me E
added
Ti me
(min)
Absorbance Percent
1#1 #1
200 110 10 No YesDionexBeginning
5 0.079 15.67
10 0.131 26.13
20 0.146 29.07
30 0.156 31.05
45 0.162 32.25
60 0.165 32.82
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingHowCooling
Time E
added
Ti me
(min)
Absorbance Percent
#1 #1
200 120 10 No YesDionexBeginning
5 0.084 16.74
10 0.109 21.69
20 0.140 27.87
30 0.170 34.01
45 0.182 36.40
60 0.176 35.0870
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
200 135 30 Yes YesDionexBeginning
5 0.1110.08622.1417.25
100.1720.14234.2228.33
200.2260.19645.0339.09
300.2560.21450.9842.66
450.2550.22650.8245.09
600.2650.23352.9346.42
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Ti me
(min)
Absorbance Percent
#I #1
200 130 10 Yes YesDionexBeginning
5 0.053 10.56
10 0.129 25.69
20 0.219 43.78
30 0.287 57.24
45 0.315 62.90
60 0.323 64.52
Conditions during the Treatment Dissolution Study Data
P (atm)T ("C)
Treatment
Time
(min)
MixingFlowCooling
T ime E
added
Ti me
(min)
Absorbance Percent
#1 #2 #1 #2
200 135 30 Yes YesDionexBeginning
5 0.0310.018 6.21 3.68
100.2240.16844.7533.52
200.3940.43578.6586.87
300.4270.45285.2490.16
450.4540.47890.6495.33
600.4870.45897.0691.3271
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCoolingTime E
added
Time
(min)
Absorbance Percent
#1 #1
200 140 10 No YesDionexBeginning
5 0.326 64.96
10 0.440 87.80
20 0.384 76.57
30 0.347 69.14
45 0.333 66.50
60 0.351 69.96
Conditions during the Treatment Dissolution Study Data
P (atm)T CO
Treatment
Time
(min)
MixingFlowCoolingTime E
added
Ti me
(min)
Absorbance Percent
#1 #1
300 110 10 No YesDionexBeginning
5 0.065 12.92
10 0.114 22.83
20 0.140 27.84
30 0.155 30.92
45 0.155 31.01
60 0.158 31.61
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Ti me
(min)
Absorbance Percent
#1 #1
300 120 10 No YesDionexBeginning
5 0.149 29.72
10 0.176 35.02
20 0.181 36.05
30 0.184 36.67
45 0.189 37.61
60 0.195 38.8372
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(mi n)
MixingFlowCoolingTime E
added
Time
(min)
Absorbance Percent
#1 #1
300 120 10 Yes YesDionexBeginning
5 0.075 15.00
10 0.138 27.52
20 0.164 32.64
30 0.173 34.56
45 0.178 35.58
60 0.180 35.92
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(MI TI)
MixingFlowCoolingTime E
added
Time
(mm)
Absorbance Percent
#1 #2 #1 #2
300 130 10 No NoDionexBeginning
50.0650.05912.9211.76
100.2190.20643.6441.00
200.3000 .29359.9058.436
300.3190.31063.58261.82
450.3280.31865.3463.43
600.3310.32666.1164.99
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingFlowCoolingTime E
added
Time
(min)
Absorbance Percent
#1 #1
300 130 60 Yes NoDionex End
5 0.049 9.80
10 0.140 27.96
20 0.456 90.88
30 0.490 97.67
45 0.506 100.94
60 0.498 99.3173
Conditions during the Treatment Dissolution Study Data
P (atm)
T
Treatment
Time
(min)
MixingFlowCoolingg
.--
Time F
added
Time
(min)
Absorbance Percent
#1 #2 #3 #1 #2#3
300 130 10 No YesDionexBeginning
50.1340.0980.06526.7519.4613.05
100.2510.2450.25749.9948.8751.30
200.3460.3060.30168.9460.9959.97
300.3590.3340.32571.6466.6564.93
450.3760.3510.34874.9670.0869.42
600.3880.3520.35577.4670.2470.92
Conditions during the Treatment Dissolution Study Data
P (atm)
T
( °C)
Treatment
Time
(min)
MixingFloNNCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #3 #1 #2 #3
1 150 10 Yes NoDionexBeginning
50.0440.0460.0418.829.138.25
100.1720.1940.16815.9038.6833.58
200.3260.3830.35544.2976.3970.83
300.3810.4960.45069.3698.9589.85
450.4190.4940.47995.7198.6295.64
600.4250.5110.51299.57102.0102.1
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatmen
t Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
300 130 30 No YesDionexBeginning
5 0.0570.032 11.44 6.43
100.1490.12829.64 25.60
200.2980.319 59.38 63.55
300.3590.36871.56 73.47
450.3800.38675.7677.00
600.3830.391 76.35 78.0874
Conditions during the Treatment Dissolution Study Data
P (atm)I ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(nun)
Absorbance Percent
#1 #2 #1 #2
300 130 10 Yes YesDionexBeginning
5 0.0520.08910.3717.68
100.1850.18936.8537.69
200.3000.27359.9154.38
300.3580.29871.4559.50
450.4020.31080.1761.92
600.3980.33779.3967.24
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #1
300 130 10 Yes YesDionex End
5 0.044 8.85
10 0.253 50.39
20 0.394 78.63
30 0.381 75.96
45 0.391 77.95
60 0.398 79.44
Conditions during the Treatment Dissolution Study Data
P(atm)T (°C)
Treatment
Time
(min)
MixingFlowCooling
Ti me ETime
(min)
Absorbance Percent
#1 #2 #1 #2
300 130 10 No YesDry iceBeginning
50.0540.13010.6926.01
100.1970.21339.2242.43
200.2810.27056.1553.76
300.3200.29963.7959.64
450.3410.31967.9363.66
600.3400.32567.7764.9075
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time ETime
(min)
Absorbance Percent
#1 #2 #1 #2
300 135 10 Yes YesDionexBeginning
5 0.0590.06511.7813.05
10 0.1330.17326.4534.41
20 0.2220.26044.3651.90
30 0.3190.31063.6361.78
45 0.3690.35773.5271.13
60 0.3920.37278.1074.20
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
300 135 20 YesYesDionexBeginning
5 0.0580.03711.497.395
10 0.2150.18042.8835.82
20 0.3460.37269.0774.19
30 0.4160.44182.9087.90
45 0.4470.44789.2189.11
60 0.4550.45990.7091.58
Conditions during the Treatment Dissolution Study Data
P
(atm)
T ("C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2#3 #1 #2#3
300135 30 Yes YesDionexBeginning
50.0200.0260.0154.085.182.95
100.1620.1320.16631.1426.3933.02
200.3000.3350.35665.7266.8870.94
300.3550.4350.42384.8186.7184.42
450.3680.4940.442100.898.5688.15
600.3770.5100.479101.5101.895.4976
Conditions during the Treatment Dissolution Study Data
P (atm)T ("C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
300 135 30 Yes NoDionexBeginning
50.0440.0518.7410.24
100.1620.18932.2437.72
200.3000.32459.0464.62
300.3550.35670.7471.01
450.3680.37573.4774.79
600.3770.39075.1177.85
Conditions during the Treatment Dissolution Study Data
P (atm)T ("C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
300 135 60 Yes YesDionexBeginning
5 0.0380.0157.502.95
100.1510.12130.0324.13
200.2540.22350.7644.48
300.3100.29561.8158.88
450.3210.31464.1262.64
600.3520.33370.2366.48
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
Mixing CoolingTime E
added
Time
(min)
Absorbance Percent
#1 #1
300 140 10 No YesDionexBeginning
5 0.146 29.11
10 0.188 37.44
20 0.198 39.44
30 0.298 59.36
45 0.322 64.16
60 0.340 67.9177
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCoolingTime E
added
Time
(min)
Absorbance Percent
#1 #1
400 110 10 No YesDionexBeginning
5 0.110 21.86
10 0.124 24.72
20 0.096 19.10
30 0.139 27.77
45 0.147 29.28
60 0.145 28.83
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Percent
#1 #1
400 120 10 No YesDionexBeginning
5 0.104 20.65
10 0.161 32.11
20 0.202 40.32
30 0.170 33.99
45 0.174 34.71
60 0.181 36.14
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Percent
#1 #2 #1 #2
400 130 10 No YesDionexBeginning
50.1210.07324.0914.65
100.2240.24044.6147.89
200.2850.30056.7959.86
300.3310.29566.0858.77
450.3410.30568.1260.76
600.3510.29170.0458.0478
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #1
400 130 10 Yes YesDionexBeginning
5 0.082 14.65
10 0.173 47.89
20 0.227 59.86
30 0.255 58.77
45 0.303 60.76
60 0.289 58.04
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #2 #1 #2
400 135 30 Yes YesDionexBeginning
50.0290.0475.72 9.41
100.1480.17629.6235.15
200.1790.21535.6442.95
300.2300.31545.9862.86
450.3160.35663.0171.02
600.3520.38270.3276.26
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #1
400 140 It) No YesDionexBeginning
5 0.044 8.74
10 0.145 29.00
20 0.250 49.89
30 0.301 60.03
45 0.328 65.41
60 0.358 71.4779
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Ti me E
added
Time
(min)
Absorbance Percent
#1 #1
1 130 10 No NoDionexBeginning
5 0.065 12.91
10 0.137 27.30
20 0.183 36.47
30 0.200 39.82
45 0.208 41.57
60 0.209 41.76
Conditions during the Treatment Dissolution Study Data
P (atm)T CC)
Treatment
Time
(min)
MixingFlowCoolingTime Time ETime
i
Percent
#1 #2 #1 #2
1 130 10 Yes NoDionexBeginning
50.0670.11013.3921.85
100.1410.17028.0334.00
200.1700.13033.8325.83
300.1920.15938.3231.75
450.1980.17139.5734.13
600.2060.19541.0438.95
Conditions during the Treatment Dissolution Study Data
P (atm)T (°C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #1
1 130 10 Yes NoDionex End
5 0.112 22.31
10 0.245 48.80
20 0.332 66.24
30 0.302 60.17
45 0.235 46.85
60 0.281 56.0280
Conditions during the Treatment Dissolution Study Data
P (atm)T ( °C)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Ti me
(min)
Absorbance Percent
#1 #2 #1 #2
1 135 10 Yes NoDionexBeginning
50.0860.08117.2016.14
100.1540.15830.6631.60
200.2110.19041.9937.94
300.2200.20343.9340.47
450.2260.20745.1041.23
600.2250.20444.9640.65
Conditions during the Treatment Dissolution Study Data
P (atm)T C C)
Treatment
Time
(min)
MixingFlowCoolingTime E(lime
)
Absorbance Percent
#1 #2 #1 #2
1 145 10 Yes NoDionexBeginning
50.0750.01515.002.97
100.2430.13048.5625.91
200.2920.24558.2948.81
300.3040.29660.5559.04
450.3040.31860.5863.37
600.3270.32765.2265.25
Conditions during the Treatment Dissolution Study Data
P (atm)T (V)
Treatment
Time
(min)
MixingFlowCooling
Time E
added
Time
(min)
Absorbance Percent
#1 #1
1 150 10 No NoDionexBeginning
5 0.024 4.70
10 0.172 34.35
20 0.326 65.00
30 0.281 75.97
45 0.419 83.50
60 0.425 84.7181
*I E is explotab.
Beginning means adding explotab at the beginning with other ingredients.
End means adding explotab after mixing other ingredients well until 120 °C.
?*- Dionex is the cooling system inside the SFE -703 Extraction System from
Dionex.